June 2020
Volume 61, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2020
Calcium Channel Blocker Use and Risk of Glaucoma in a Large United Kingdom Population
Author Affiliations & Notes
  • Alan Kastner
    NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
    Pontificia Universidad Catolica de Chile, Santiago, Chile
  • Giovanni Montesano
    Division of Optometry and Vision Science - City, University of London, London, United Kingdom, London, United Kingdom
  • C Gustavo De Moraes
    Columbia University Medical Center, New York, New York, United States
  • Jae H. Kang
    Channing Division of Network Medicine, Brigham and Women's Hospital / Harvard Medical Schoo, Boston, Massachusetts, United States
  • Janey Wiggs
    Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • Louis Pasquale
    Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Pirro G Hysi
    Section of Ophthalmology, School of Life Course Sciences and Medicine, King’s College, London, United Kingdom
    Department of Twin Research and Genetic Epidemiology, King’s College, London, United Kingdom
  • Sharon Chua
    NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Praveen J Patel
    NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Paul J Foster
    NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Sir Peng T. Khaw
    NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Anthony Khawaja
    NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Footnotes
    Commercial Relationships   Alan Kastner, None; Giovanni Montesano, CenterVue (C); C Gustavo De Moraes, Belite (C), Carl Zeiss (C), Galimedix (C), Heidelberg (R), NIH (R), Novartis (C), Perfuse Therapeutics (C), Reichart (C), Research to Prevent Blindness (R), Topcon (R); Jae Kang, None; Janey Wiggs, Aerpio (F), Allergan (C), Editas (C), Maze (C), Regenxbio (C); Louis Pasquale, Bausch+Lomb (C), Emerald Bioscience (C), Eyenovia (C), Nicox (C), Verily (C); Pirro Hysi, None; Sharon Chua, None; Praveen Patel, None; Paul Foster, 90Ten (C), AlphaSights (C), DeepMind/Google (C), GLG (C), InHouse Research (C), Simon Kucher (C); Sir Peng Khaw, Aerie Pharmaceuticals (C), Alcon (C), Belkin (C), Glaukos (C), GLG (C), ISARNA (C), Muller Cells (P), Novartis (C), Radiance (I), Radiance Tx (C), Santen Pharmaceuticals (C), Thea Pharmaceuticals (C), Valid Insight (C); Anthony Khawaja, Aerie (C), Allergan (C), Google (C), Novartis (C), Santen (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 2739. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alan Kastner, Giovanni Montesano, C Gustavo De Moraes, Jae H. Kang, Janey Wiggs, Louis Pasquale, Pirro G Hysi, Sharon Chua, Praveen J Patel, Paul J Foster, Sir Peng T. Khaw, Anthony Khawaja; Calcium Channel Blocker Use and Risk of Glaucoma in a Large United Kingdom Population. Invest. Ophthalmol. Vis. Sci. 2020;61(7):2739.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Evidence from insurance claims data suggests an increased risk of primary open angle glaucoma (POAG) with the use of systemic calcium channel blockers (CCBs). We aimed to further examine the association of CCB use with POAG and related traits in a very large UK population-based cross-sectional study.

Methods : We used data from the UK Biobank, a multisite cohort study of over 500,000 participants. An eye-health related questionnaire and examination were introduced in the latter part of the study (2009-2010). POAG status was ascertained by a combination of self-report on a baseline questionnaire and linkage with hospital procedure data (ICD-10 code H40.1). Corneal compensated intraocular pressure (IOP) was measured using the Ocular Response Analyser and pre-treatment values for those on glaucoma medication imputed by dividing by 0.7. Macular retinal nerve fiber layer (mRNFL) and ganglion cell-inner plexiform layer (GCIPL) thicknesses were derived from spectral-domain optical coherence tomography (OCT) scans (Topcon 3D OCT-1000 Mark II). Refractive status was measured by autorefraction (Tomey RC5000). CCB use was ascertained by interview. We used logistic regression to examine the association between CCB use and POAG, and linear regression to examine the associations between CCB use and IOP, GCIPL and mRNFL. All analyses were adjusted for age, sex, spherical equivalent and ethnicity.

Results : In total, we included 121,967 participants with a mean age of 57 years. Of these, 2,328 (1.9%) had POAG and 10,760 (8.8%) were using CCBs. CCB use was associated with an increased prevalence of POAG (OR 1.20, 95% CI: 1.06, 1.34, P=0.002). For analyses of IOP and macular thickness, there were complete data for 116,358 and 43,085 participants, respectively. There was no significant association between CCB use and IOP (-0.02 mmHg, 95% CI: -0.10, 0.06, P=0.63). CCB use was associated with a thinner mRNFL (-0.28 μm, 95% CI: -0.42, -0.15, P=2.8x10-5) and a thinner GCIPL (-0.54 μm, 95% CI: -0.71, -0.36, P=2.3x10-9).

Conclusions : Our study provides further evidence that CCBs might increase the risk of POAG. The magnitude of association was substantial (20% increased prevalence in users). The significant association with inner retinal thickness but not with IOP suggests that the potential harmful effect of CCBs is mediated via IOP-independent mechanisms.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×